[go: up one dir, main page]

MX2024011083A - Anticuerpos multiespecíficos y usos de estos. - Google Patents

Anticuerpos multiespecíficos y usos de estos.

Info

Publication number
MX2024011083A
MX2024011083A MX2024011083A MX2024011083A MX2024011083A MX 2024011083 A MX2024011083 A MX 2024011083A MX 2024011083 A MX2024011083 A MX 2024011083A MX 2024011083 A MX2024011083 A MX 2024011083A MX 2024011083 A MX2024011083 A MX 2024011083A
Authority
MX
Mexico
Prior art keywords
antigen
binding
nucleic acids
multispecific antibodies
region capable
Prior art date
Application number
MX2024011083A
Other languages
English (en)
Inventor
Sanjaya Singh
Danlin Yang
Bidisha Dasgupta
Rupesh Nanjunda
Adam Zwolak
Wilson Edwards
Rosario Brian Del
Thomas Kelly
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2024011083A publication Critical patent/MX2024011083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan anticuerpos multiespecíficos o fragmentos de unión al antígeno de estos que comprenden al menos una primera región de unión al antígeno capaz de unirse específicamente al piroglutamato amiloide-ß, una segunda región de unión a antígeno capaz de unirse específicamente al receptor de transferrina (TfR), y una tercera región de unión al antígeno capaz de unirse específicamente al filamento helicoidal emparejado (PHF)-tau. También se proporcionan métodos para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, vectores que comprenden los ácidos nucleicos, células huéspedes recombinantes que comprenden los ácidos nucleicos y/o vectores, y métodos para producir los anticuerpos multiespecíficos o los fragmentos de unión al antígeno de estos.
MX2024011083A 2022-03-11 2024-09-10 Anticuerpos multiespecíficos y usos de estos. MX2024011083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269208P 2022-03-11 2022-03-11
PCT/EP2023/056225 WO2023170295A1 (en) 2022-03-11 2023-03-10 Multispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024011083A true MX2024011083A (es) 2024-12-06

Family

ID=85601592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011083A MX2024011083A (es) 2022-03-11 2024-09-10 Anticuerpos multiespecíficos y usos de estos.

Country Status (11)

Country Link
US (1) US20250136672A1 (es)
EP (1) EP4490185A1 (es)
JP (1) JP2025512732A (es)
KR (1) KR20240161964A (es)
CN (1) CN119173530A (es)
AU (1) AU2023232448A1 (es)
CA (1) CA3254615A1 (es)
IL (1) IL315540A (es)
MX (1) MX2024011083A (es)
TW (1) TW202345899A (es)
WO (1) WO2023170295A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118459582B (zh) * 2024-07-11 2024-11-15 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA3093200A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
BR112021019107A2 (pt) 2019-03-26 2021-11-30 Janssen Pharmaceutica Nv Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
EP4132589A4 (en) 2020-04-08 2024-05-08 Aliada Therapeutics, Inc. COMPOSITIONS AND METHODS OF ADMINISTRATION AT THE BLOOD-BRAIN BARRIER
KR20220166308A (ko) * 2020-04-08 2022-12-16 얀센 바이오테크 인코포레이티드 항-phf-타우 항체 및 이의 용도

Also Published As

Publication number Publication date
KR20240161964A (ko) 2024-11-13
JP2025512732A (ja) 2025-04-22
AU2023232448A1 (en) 2024-10-24
CA3254615A1 (en) 2023-09-14
IL315540A (en) 2024-11-01
WO2023170295A1 (en) 2023-09-14
US20250136672A1 (en) 2025-05-01
TW202345899A (zh) 2023-12-01
CN119173530A (zh) 2024-12-20
EP4490185A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
CO2021002965A2 (es) Moléculas de ácido nucleico y sus usos para la terapia génica no viral
BR112022020275A2 (pt) Composições e métodos para distribuição à barreira hematoencefálica
MX2024011083A (es) Anticuerpos multiespecíficos y usos de estos.
AR127518A2 (es) Anticuerpos anti-cd98 y usos de estos
US8129506B2 (en) Modulation of the interaction of MUC1 with MUC1 ligands
CA2965033C (en) Methods and compositions for diagnosis and treatment of glioblastoma
Fukai et al. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
JP6500933B2 (ja) 食道がんのマーカーおよびその利用
WO2002046208A2 (en) Method of producing biospecific molecules by protein trans-splicing
AU2002241556A1 (en) Method of producing bispecific molecules by protein trans-splicing
WO2016019472A1 (en) Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
MX2024011081A (es) Anticuerpos multiespecíficos y usos de estos.
MX2024011080A (es) Anticuerpos multiespecíficos y usos de estos.
CN102272157B (zh) 用于抑制cripto/grp78复合物形成和信号的组合物和方法
Schellhammer et al. Exit pathways of therapeutic antibodies from the brain and retention strategies
JP7777071B2 (ja) 抗α－シヌクレインモノクローナル抗体およびその使用法
Ma et al. Canstatin represses glioma growth by inhibiting formation of VM-like structures
Kim et al. Complementary treatment of siTERT for improving the antitumor effect of TERT-specific I-131 therapy
US11369669B2 (en) Measles virus encoding a tumor antigen
UY40013A (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ralfa, Y U
CN107417788A (zh) 抗埃博拉病毒的中和性单克隆抗体
WO2022150379A1 (en) Nk cell engager molecules and methods of use
JPWO2020043750A5 (es)
US20240368605A1 (en) Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2